Cyclica Inc., a Toronto, ON-based startup that uses big data and applied analytic techniques to increase productivity in pharmaceutical research and development, received an investment from GreenSky Accelerator Fund I, LP.
The amount of the transaction was not disclosed.
The company’s seed funding, which is still open to angel investors, will be used to accelerate growth.
Led by CEO Paul Angelico, Cyclica uses Ligand Express™, its proprietary computational analysis technology, to develop pharmaceutical drugs, nutraceuticals ingredients, and personal care products.
The platform simulates the interaction of compounds (e.g. drug candidates, nutraceuticals, and personal care products) with all aspects of human biology (i.e. all known proteins).
Through a partnership with IBM Research, the company is now creating vast stores of proprietary data for analyzing cross reactivity of molecules to assess safety and efficacy.